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Abstract. Obesity is usually associated with a decreased response 
to insulin, a major metabolic defect known as insulin resistance 
and an early trait in the development of type 2 diabetes. The c-Jun 
N-terminal kinase (JNK) pathway has emerged as a central 
regulator of insulin sensitivity, locally and systemically, thereby, 
of body’s metabolic homeostasis. As the incidence of obesity and 
type 2 diabetes has alarmingly increased in the last few decades, 
there is a tremendous necessity to identify novel pharmacological 
targets to efficiently improve the therapeutic outcome. In this 
regard, the JNK pathway seems to meet most of the requirements 
for being an adequate candidate to direct pharmacological 
intervention. 
 
Introduction 
 
      The incidence of type 2 diabetes is alarmingly increasing worldwide 
specially as a result of the tremendous rise in obesity, a major risk factor for 
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the development of this disease. Decreased sensitivity of target tissues to 
insulin, known as insulin resistance, is an early trait in the development of 
type 2 diabetes and results in glucose intolerance; afterwards, failure                         
of pancreatic insulin-secreting cells (β-cells) is the major determinant                   
of progression to hyperglycemia, the hallmark of diabetes. Insulin 
resistance is strongly associated to obesity; its incidence in the population 
parallels that of obesity; and represents the link of obesity to type 2 
diabetes [1].  
 Insulin resistance is a major metabolic disorder and develops because 
defective insulin receptor (IR) signaling in insulin-target tissues such as 
liver, adipose tissue and skeletal muscle, among others. The etiology of 
insulin resistance has been the focus of intensive research, and it is 
currently accepted that chronic inflammation is an important cause [2]. In 
this regard, obesity, which is the most common origin for the development 
of insulin resistance, is usually associated with a low-grade, chronic 
inflammatory state that initially affects the adipose tissue but at latter 
stages spreads out to other tissues because the fat accumulation at these 
anomalous locations [3]. Other conditions associated to the expansion of 
the adipose tissue such as the increased production of reactive oxygen 
species (ROS) or the endoplasmic reticulum (ER) stress also promote 
insulin resistance either directly or through the enhancement of the 
inflammatory response [4]. At molecular level, pro-inflammatory 
cytokines are main players in promoting insulin resistance, as they are 
activators of signaling pathways, such as the c-Jun N-terminal kinase 
(JNK) and the inhibitor of nuclear factor κ-B kinase (IKK) pathway, that 
negatively interfere with the early steps in the IR signaling cascade [5]. In 
this chapter we are going to focus the attention on the physiopathological 
role of the JNK pathway on the regulation of insulin sensitivity. 
 
1. The JNK signaling pathway 
 
 JNK comprises a group of serine/threonine protein kinases that belongs 
to the stress-activated protein kinase (SAPK) subfamily of mitogen-activated 
protein kinases (MAPKs). MAPKs participate in ubiquitous and 
evolutionary conserved signal transduction pathways in eukaryotes. MAPK 
pathways enable coordinated responses to a vast array of stimuli regulating 
different cellular processes such as gene transcription, mRNA stability, 
protein synthesis, cell proliferation, cell differentiation, or apoptosis. The 
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MAPKs are the final step of a protein kinase cascade (the MAPK module) 
composed, in addition to the MAPK, by a MAPK kinase (MAP2K), and a 
MAP2K kinase (MAP3K), which are sequentially activated through 
phosphorylation by the upstream kinase. In addition, non-enzymatic scaffold 
proteins may also participate in these MAPK modules to stabilize physical 
interactions and/or promote recruitment of the components. MAPK modules 
enhance efficiency and selectivity in signal transmission. MAPKs are 
activated by dual phosphorylation on tyrosine and threonine residues within 
the evolutionary conserved Thr-Xxx-Tyr motif located in their activation 
loop. MAPKs are proline directed kinases thus; they phosphorylate serine 
and threonine residues followed by a proline, though engagement of 
substrates requires additional interactions out of the catalytic site mediated 
by specific docking sites located apart of the phosphorylation sites. MAPKs 
are inactivated by dephosphorylation performed by protein phosphatases 
such as the MAP kinase phosphatase (MKP)/dual specificity phosphatase 
(DUSP)-1 [6]. 
 JNK was initially identified as the major protein kinase responsible for 
the phosphorylation of residues at the N-terminal/transactivation domain of 
c-Jun, a component of the AP-1 complex, triggering its transactivation 
function (Fig. 1) [7-9]. The JNK signalling pathway is preferentially 
activated by pro-inflammatory signals, such as tumor necrosis factor (TNF)-
α or interleukin (IL)-1β, and stress stimuli, such as ultraviolet (UV), ER 
stress and ROS. Consistently, JNK pathway is a target of anti-inflammatory 
drugs such as glucocorticoids, which efficiently repress the activation of the 
JNK pathway by different mechanisms [10-12]. 
 JNKs are encoded by three genes, jnk-1, jnk-2, and jnk-3, which through 
alternative splicing mechanisms give rise up to twelve different isoforms. 
Expression of jnk-1 and jnk-2 is ubiquitous whereas jnk-3 is expressed in a 
tissue specific manner [13,14]. The MAP2K MKK4 and MKK7 catalyze the 
phosphorylation, and concomitant activation, of JNK. Whereas MKK4 also 
phosphorylates the MAPK p38, MKK7 is highly specific for JNK and other 
substrates have not been identified so far for this protein kinase. 
Accordingly, MKK4 and MKK7 show nonredundant functions in vivo. For 
instance, MKK4 activates JNK in response to stress stimuli, such as 
anisomycin or heat-shock, whereas MKK7 is required for JNK activation by 
pro-inflammatory signals [15,16]. Consistent with the variety of stimuli that 
activate the JNK pathway, a diverse group of MAP3Ks phosphorylate, and 
concomitantly activate, MKK4 and/or MKK7 [6]. 
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Figure 1. Regulation of the AP-1-dependent gene transcription by the JNK pathway. 
In non-stimulated conditions, protein kinases (MAP3K: MLK, MAP2K: MKK7, and 
MAPK: JNK) and scaffolds (JIP-1) of the JNK pathway module are pre-assembled in 
the cytoplasm but inactive. In the nucleus, AP-1 complexes are associated to their 
cognate DNA binding elements, known as TPA response elements (TREs), but the 
interaction of co-repressors (R) with c-Jun, a component of the AP-1 complex, 
inhibits transcription of the AP-1 target genes. Upon stimulation, the protein kinases 
in the module are sequentially activated by phosphorylation (phosphotyrosine and 
phosphoserine/phosphothreonine are indicated in magenta and orange dots, 
respectively). Activated JNK dissociates from the module and translocates into the 
nucleus where interacts and phosphorylates c-Jun at specific sites in its 
transactivation domain. c-Jun phosphorylation induces the dissociation of co-
repressors allowing the interaction with co-activators (A), consistently, the AP-1-
dependent gene transcription is induced.  MKP-1, a nuclear protein phosphatase, 
inactivates JNK by dephosphorylation, and inactive JNK returns to the cytoplasm. 
 
2. The IR signaling pathway 
 
 Insulin is a hormone secreted by the pancreatic β-cells in response to an 
increase in glycemia. It has very important endocrine functions mostly, but 
not exclusively, related to carbohydrate and lipid homeostasis. Insulin 
reduces glycemia by promoting glucose uptake in adipose tissue and skeletal 
muscle and suppressing hepatic gluconeogenesis. In addition, insulin 
promotes glycogen, lipid and protein synthesis in target tissues. Insulin 
signaling is triggered by its binding of the IR, a receptor that belongs to the 
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tyrosine kinase receptor family and that is composed by two extracellular 
subunits (  chains) and two transmembrane subunits (β chains). Hormone 
engagement activates the intrinsic tyrosine kinase activity of the IR resulting 
in the autophosphorylation on the β subunit cytoplasmic tails. These 
phosphotyrosine residues are docking sites for the recruitment of proteins 
from the IR substrate (IRS) family, such as IRS-1 or IRS-2. IRS-1/2 are also 
phosphorylated on tyrosine residues by the IR resulting in the generation of a 
docking platform for proteins of the IR signaling, such as the subunit of the 
phosphatidylinositol-3-kinase (PI3K), p85, or the Grb2-SOS adaptor Shc.  
 
Figure 2. Insulin-induced JNK activation inhibits IR signaling by phosphorylation of 
IRS-1 on serine-307. Insulin binding to the IR triggers its tyrosine kinase activity 
eliciting the autophosphorylation on tyrosine residues (magenta dots) of the 
cytoplasmic tails of the IR β subunits. These phosphotyrosine residues are docking 
sites for the recruitment of proteins from the IRS family such as IRS-1. Upon 
interaction, IRS-1 is phosphorylated on tyrosine residues by the IR resulting in the 
generation of a docking platform for the interaction with a variety of proteins 
involved in IR signaling. Insulin induces the activation of JNK, which in turn binds 
to IRS-1 and phosphorylates it on serine-307 (orange dot). IRS-1 phosphorylation on 
serine-307 disrupts its interaction with the IR ensuing the physiological down-
regulation of IR signalling. 
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 IR-activated PI3K promotes AKT activation, which eventually elicits 
the regulation of glucose metabolism and protein synthesis, and, through the 
sterol-regulatory element binding protein (SREBP)-1c, the metabolism of 
lipids. In contrast, insulin mitogenic effects are mostly mediated by the 
induction of the SOS-Ras-extracellular signal-regulated protein kinase 
(ERK) signaling pathway (Fig. 2) [17]. 
 IRS-1 and IRS-2 are tightly regulated by phosphorylation on multiple 
serine/threonine residues mediated by several insulin-stimulated protein 
kinases, an autologous mechanism that regulates, positively or negatively, 
insulin sensitivity [18]. Concretely, IRS-1 phosphorylation on serine-307 is 
induced by insulin and inhibits IRS-1 interaction with the insulin-activated 
IR, thereby inhibits IR signaling. Serine-307 is targeted by JNK, which is 
activated in response to insulin and in this manner operates as a negative 
feedback mechanism to turn off IR signalling in physiological conditions 
(Fig. 2) [19-21]. Likewise, IRS-2 is also phosphorylated by JNK on serine-
488 with similar functional consequences [22]. 
 
3. Obesity-induced insulin resistance and the JNK pathway 
 
 The relationship between obesity-induced insulin resistance and 
inflammation originates with the observation of an increased TNF-  gene 
expression in adipose tissue of obese rodents, which turns into increased 
levels of this cytokine locally and, eventually, systemically. Moreover,  
TNF-  neutralization in these animals improved insulin sensitivity [23]. In 
the following years, many studies have contributed to decipher the cellular 
and molecular mechanisms underlying the role of inflammation in the 
promotion and progression of obesity-induced insulin resistance, however 
most of them are out of the scope of this revision hence they will not be 
mentioned but are profoundly reviewed in references 2 to 5. 
 In obesity there is an overexpansion of the adipose tissue that is 
accomplished by processes of adipocyte hyperplasia and hypertrophy. 
Hypertrophic adipocytes undergo a series of perturbations such as an 
increased demand on the synthetic machinery, an accumulation of unfolded 
proteins in the ER or an excessive production of ROS that generate stress in 
the ER. To restore organelle functionality a response known as the unfolded 
protein response (UPR) emanates from the ER. The UPR is a complex 
response system with different branches but notably one of them, mediated 
by the inositol-requiring enzyme (IRE)-1, activates JNK through a pathway 
involving TNF-receptor associated factor (TRAF)-2 [24]. This activation of 
JNK leads to IRS-1/2 phosphorylation with the concomitant inhibition of IR 
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signaling. In addition, the JNK pathway-induction of pro-inflammatory gene 
expression works as a feed-forward mechanism to further increase JNK 
activity. In this scenario, this chronically activated JNK leads to the 
promotion of insulin resistance (Fig. 3). In addition, in obesity there is an 
increase in the systemic level of free fatty acids (FAA), which by binding to 
the Toll-like receptors activate the JNK pathway and, thereby, foster insulin 
resistance [25]. 
 
 
 
Figure 3. Obesity-induced JNK activation induces insulin resistance through IRS-1 
phosphorylation on serine-307. In obesity there are conditions, such as the increased 
level of pro-inflammatory cytokines (TNF- ) and ROS, or the induction of ER stress, 
that exacerbate the activity of the JNK pathway by a TRAF-2-dependent induction of 
phosphorylation, and concomitant activation, of the protein kinases of the JNK 
module (magenta and orange dots on ASK-1, MKK7 and JNK, respectively). This 
obesity-induced JNK activity inhibits IR signaling through the phosphorylation of 
IRS-1 on serine-307 (orange dot). In addition, enhanced expression of pro-
inflammatory mediators, such as the TNF- , mediated by the JNK pathway further 
contributes to the inhibition of IR signaling mediated by the JNK-dependent IRS-1 
phosphorylation. Thereby, in this scenario of chronically exacerbated JNK activity 
insulin resistance develops. 
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 In accordance with this, JNK activity is augmented in tissues such as 
liver, adipose tissue, and skeletal muscle of obese humans [26] and rodents 
[27]. Moreover, a central role of the JNK pathway on obesity-induced 
insulin resistance is also substantiated by genetic data. 
 Epidemiologic studies identified the gene encoding the JNK interacting 
protein (JIP)-1, a scaffold protein of the JNK module, as a candidate for  
type 2 diabetes [28]. In addition, JIP-1-genetic deficiency in mice prevents 
obesity-induced activation of JNK in adipose tissue and protects from diet-
induced obesity and insulin resistance [29]. 
 Moreover, jnk-1-deficient mice are protected from the development of 
adiposity and show significantly improved insulin sensitivity and enhanced 
IR signalling in diet- and genetically-induced obesity mouse models [27]. 
This study demonstrated that JNK-1 isoform has a prominent role in 
obesity-induced insulin resistance given that jnk-2-deficient mice showed a 
wild type phenotype [27]. However, the fact that jnk-2-deficient mice 
heterozygous for jnk-1 are also protected from diet-induced obesity and 
insulin resistance points to a compensatory role of JNK-1 in the absence of 
JNK-2 [30].  
 The pivotal role of JNK in obesity-induced insulin resistance has 
strongly instigated the pharmacological targeting of the JNK pathway as a 
therapeutic approach for the treatment of type 2 diabetes. In this regard, 
treatment of obese mice with a small molecule inhibitor of JNK improved 
insulin sensitivity [31]. 
 Notably, it has been described that thiazolidinediones (TZDs), a group 
of synthetic peroxisome proliferator-activated receptor (PPAR)-γ ligands 
used in clinics because their insulin-sensitizing activity [32], are active in the 
inhibition of obesity-induced JNK activity in insulin-target tissues such as 
liver and adipose tissue. Indeed, the lack of TZD antidiabetes action in obese 
jnk-1-deficient mice indicates that JNK inhibition mediates this 
pharmacological property. Moreover, PPAR-γ is expressed in immune cells, 
such as macrophages, and in adipocytes; therefore, TZDs may inhibit JNK in 
both cellular compartments, immune and metabolic, of the adipose tissue, 
and regardless the nature of the stimuli, a pro-inflammatory cytokine or a 
stress mediator (Fig. 4) [33]. 
 The contribution of tissue-specific JNK activity on insulin sensitivity 
has been studied in transgenic mice by tissue specific genetic inactivation of 
jnk-1, or to a lesser extend jnk-2, or over-expression of dominant-negative or 
constitutively-activated forms of JNK or its immediately activating kinase, 
MKK7. 
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 Adipose-tissue specific jnk-1 genetic ablation does not prevent from 
adiposity but protects from the development of insulin resistance in adipose 
tissue and liver induced by a high-fat diet. This effect on hepatic insulin 
sensitivity seems to be mediated by the reduction in the interleukin (IL)-6 
release from the adipose tissue [34].  
 
 
 
Figure 4. TZD insulin-sensitizing action is mediated by inhibition of the JNK 
pathway in adipocytes and macrophages. In obesity, the JNK pathway is activated by 
different stimuli and inhibits IR signaling through IRS-1 phosphorylation on serine-
307 (see text and legend of Fig. 3). TZDs inhibit obesity-induced JNK activity, an 
action that requires their interaction with PPAR-γ, and, in this way, restore IR 
signaling and, thereby, insulin sensitivity.  
 
 In the liver, overall JNK activity inhibition by adenovirus-enforced 
overexpression of a dominant-negative version of JNK or by simultaneous 
inactivation of jnk-1 and jnk-2 protects against insulin resistance in diet-
induced obese mice [35,36]. In addition to the negative action of JNK on 
IR signaling through IRS-1/2 phosphorylation, the inhibitory role of JNK 
on the PPAR-α/fibroblast growth factor (FGF)21 pathway also contributes 
to this protective phenotype [36-38]. Nonetheless, there is some 
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controversy regarding the specific role of each liver JNK isoform on 
systemic glucose metabolism. On one hand, knock down of jnk-1 or jnk-2 
gene expression in the liver of obese animals resulted in reduced 
hyperglycemia and hyperinsulinemia but with distinct effects on hepatic 
steatosis [39,40]. However, single jnk-1 genetic ablation specifically in 
hepatocytes induced glucose intolerance, insulin resistance and hepatic 
steatosis in lean mice and had no effect on obese animals, indicating that 
this isoform has a protective function in this particular cell type [41]. This 
discrepancies may be due to a dual role of JNK-1 in hepatocytes that is, in 
addition to down-regulate IR signalling, JNK-1 is required for 
gluconeogenesis, lipogenesis and clearance of circulating insulin [41], in 
addition to not yet characterized interactions among the distinct cell types 
in the liver. Finally, activation of the JNK pathway by adenovirus-
mediated over-expression of wild type JNK decreased insulin sensitivity 
and augmented insulinemia due to an increased hepatic glucose production 
[35].  
 Regarding skeletal muscle, whereas jnk-1-deficiency specifically in 
this tissue does not protect from diet-induced obesity, it ameliorates 
systemic insulin resistance by preserving IR signalling locally. This 
protective effect is not widespread to adipose tissue or liver, in fact, theses 
mice showed enhanced hypertriglyceridemia, due to a reduction on muscle 
lipoprotein lipase, macrophage infiltration in adipose tissue and hepatic 
steatosis [42]. In contrast, JNK over-expression studies in skeletal muscle 
have rendered contradictory and therefore, require further analysis [43,44]. 
 JNK has also been implicated in promoting insulin resistance in 
pancreatic β-cells. In particular, FFA administration results in JNK 
activation with the concomitant inhibition of IR signalling in these cells 
[45]. Moreover, in vivo activation of JNK by over-expression of a 
constitutively active version of MKK7 in pancreatic β-cells leads to 
glucose intolerance due to the failure to secrete insulin in response to 
glycemia. Static insulin secretion assays with isolated pancreatic islets 
showed that JNK activation blocks the second phase of glucose-induced 
secretion of insulin, which depends on IR signalling [46]. In addition, JNK 
might be involved in pancreatic β-cell failure, as it is required, though not 
sufficient, for pro-inflammatory cytokine-induced apoptosis in this cell 
type [46,47]. 
 Finally, JNK also regulates glucose metabolism from the central 
nervous system (CNS). As in peripheral tissues, obesity increases JNK 
activity in the hypothalamus [48], and CNS-specific jnk-1-genetic ablation 
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protects mice from diet-induced obesity, glucose intolerance and insulin 
resistance [49,50]. This phenotype is achieved through augmented energy 
expenditure and locomotor activity [49,50]. Moreover, a similar phenotype 
was also observed in genetically modified mice lacking JNK-1 and JNK-2 
in the adenohypophysis [51]. In contrast, JNK activation in the agouti-
related peptide (AgRP)-expressing neurons of the hypothalamus induces 
obesity as a consequence of hyperphagia [52]. Altogether, these results 
indicate that at the CNS JNK regulates the activity of the hypothalamic-
pituitary-adrenal axis [49-52]. 
 
4. Conclusion 
 
 The JNK pathway is currently regarded as a promising candidate for the 
pharmacological treatment of insulin resistance and type 2 diabetes because 
its pivotal role in the control of insulin sensitivity. For instance, the ability of 
the insulin-sensitizing drugs TZDs to inhibit the JNK pathway is 
fundamental for their pharmacological action. Even though in most of the 
experimental models studied exacerbated activity of the JNK pathway is 
detrimental for metabolic homeostasis, some examples showed that 
inhibition of JNK pathway activity in a particular tissue has negative 
consequences in others. In addition, incipient studies have demonstrated 
compensatory as well as non-redundant functions between the different JNK 
isoforms. Therefore, tissue-specific and isoform-specific JNK actions on 
metabolic control require further investigations for the design of the most 
advantageous therapeutic strategy. 
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